Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 1;7(11):1077-1088.
doi: 10.2217/fvl.12.108.

Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications

James S Testa  1 , Ramila Philip
Affiliations

Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications

James S Testa et al. Future Virol. .

Abstract

Prophylactic and therapeutic vaccines against viral infections have advanced in recent years from attenuated live vaccines to subunit-based vaccines. An ideal prophylactic vaccine should mimic the natural immunity induced by an infection, in that it should generate long-lasting adaptive immunity. To complement subunit vaccines, which primarily target an antibody response, different methodologies are being investigated to develop vaccines capable of driving cellular immunity. T-cell epitope discovery is central to this concept. In this review, the significance of T-cell epitope-based vaccines for prophylactic and therapeutic applications is discussed. Additionally, methodologies for the discovery of T-cell epitopes, as well as recent developments in the clinical testing of these vaccines for various viral infections, are explained.

Keywords: MHC class I; cellular immunity; cytotoxic T cells; epitopes; humoral immunity; immunoproteomics; mass spectrometry; vaccine.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Generation of adaptive immunity in infection and vaccine response
CTL: Cytotoxic T lymphocyte; IFN: Interferon.
See this image and copyright information in PMC

References

    1. Purcell AW, Mccluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov. 2007;6(5):404–414. - PubMed
    1. Zakay-Rones Z. Human influenza vaccines and assessment of immunogenicity. Expert Rev Vaccines. 2010;9(12):1423–1439. - PubMed
    1. Doherty PC, Allan W, Eichelberger M, Carding SR. Roles of alpha beta and gamma delta T cell subsets in viral immunity. Ann Rev Immunol. 1992;10:123–151. - PubMed
    1. Eichelberger M, Allan W, Zijlstra M, Jaenisch R, Doherty PC. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med. 1991;174(4):875–880. - PMC - PubMed
    1. Epstein SL, Lo CY, Misplon JA, Bennink JR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol. 1998;160(1):322–327. - PubMed

Websites

    1. Greenbaum J. Knowledgebase and Forums/Epitope analysis in emerging H1N1 swine flu viruses/Analysis version 1.0. IEDB. IEDB Analysis Resource; 2009. p. 202. http://iedb.zendesk.com/forums/45499/entries/35037. http://tools.immuneepitope.org.

LinkOut - more resources